DNA Methylation Reduces Binding and Cleavage by Bleomycin
Overview
Affiliations
In a recent study, we described the enhanced double-strand cleavage of hairpin DNAs by Fe·bleomycin (Fe·BLM) that accompanies increasingly strong binding of this antitumor agent and suggested that this effect may be relevant to the mechanism by which BLM mediates its antitumor effects. Because the DNA in tumor cells is known to be hypomethylated on cytidine relative to that in normal cells, it seemed of interest to study the possible effects of methylation status on BLM-induced double-strand DNA cleavage. Three hairpin DNAs found to bind strongly to bleomycin, and their methylated counterparts, were used to study the effect of methylation on bleomycin-induced DNA degradation. Under conditions of limited DNA cleavage, there was a significant overall decrease in the cleavage of methylated hairpin DNAs. Cytidine methylation was found to result in decreased BLM-induced cleavage at the site of methylation and to result in enhanced cleavage at adjacent nonmethylated sites. For two of the three hairpin DNAs studied, methylation was accompanied by a dramatic decrease in the binding affinity for Fe·BLM, suggesting the likelihood of diminished double-strand cleavage. The source of the persistent binding of BLM by the third hairpin DNA was identified. Also identified was the probable molecular mechanism for diminished binding and cleavage of the methylated DNAs by BLM. The possible implications of these findings for the antitumor selectivity of bleomycin are discussed.
Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell antitumor immunity.
Yu Q, Dong Y, Wang X, Su C, Zhang R, Xu W JCI Insight. 2024; 9(17).
PMID: 39106105 PMC: 11385079. DOI: 10.1172/jci.insight.177788.
DNA methylation induces subtle mechanical alteration but significant chiral selectivity.
Zeng Y, Mao Y, Chen Y, Wang Y, Xu S Chem Commun (Camb). 2023; 59(100):14855-14858.
PMID: 38015496 PMC: 10794036. DOI: 10.1039/d3cc05211g.
The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.
Murray V, Chen J, Chung L Int J Mol Sci. 2018; 19(5).
PMID: 29734689 PMC: 5983701. DOI: 10.3390/ijms19051372.
The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.
Gautam S, Chen J, Murray V J Biol Inorg Chem. 2017; 22(6):881-892.
PMID: 28509989 DOI: 10.1007/s00775-017-1466-z.
Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.
Chen J, Yang D, Shen B, Neilan B, Murray V Bioorg Med Chem. 2016; 24(22):6094-6101.
PMID: 27745992 PMC: 5466353. DOI: 10.1016/j.bmc.2016.09.072.